In VitroActivity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.
Thein vitroactivities of delafloxacin and comparator antimicrobial agents against 6,485 bacterial isolates collected from medical centers in Europe and the United States in 2014 were tested. Delafloxacin was the most potent agent tested against methicillin-susceptibleStaphylococcus aureus(MSSA), methicillin-resistantS. aureus,Streptococcus pneumoniae, viridans group streptococci, and beta-hemolytic streptococci and had activity similar to that of ciprofloxacin and levofloxacin against certain members of theEnterobacteriaceaeOverall, the broadest coverage of the tested pathogens (Gram-positive cocci and Gram-negative bacilli) was observed with meropenem and tigecycline in both Europe and the United States. Delafloxacin was shown to be active against organisms that may be encountered in acute bacterial skin and skin structure infections, respiratory infections, and urinary tract infections.
JMI Laboratories, North Liberty, Iowa, USA.|University of Iowa, Iowa City, Iowa, USA.
M A
MA
Pfaller
JMI Laboratories, North Liberty, Iowa, USA.
H S
HS
Sader
JMI Laboratories, North Liberty, Iowa, USA.
P R
PR
Rhomberg
JMI Laboratories, North Liberty, Iowa, USA robert-flamm@jmilabs.com.
R K
RK
Flamm
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005060:Europe; D024841:Fluoroquinolones / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D014481:United States
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C477891:delafloxacin
MRSA; delafloxacin